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Abstract 
 
Schizophrenia is a debilitating and costly mental illness. Many patients do not respond well 
to currently available treatments, and adverse side effects are common. Cannabidiol (CBD), a 
natural component of the Cannabis Sativa plant, has been shown to have a number of 
therapeutic qualities, including potential as a new antipsychotic. Although CBD has been 
used in several different models of schizophrenia, previous research has failed to consider 
possible sex differences in responsiveness to the compound. The present research therefore 
used both male and female rats in the widely used ketamine model of schizophrenia. PVG/C 
Hooded rats were randomly assigned to one of four experimental conditions: a saline only 
control group (saline injection followed by second saline injection; N = 6M, 6F); ketamine 
only group (ketamine injection followed by saline injection; N = 6M, 6F); cannabidiol low 
dose group (ketamine injection followed by a cannabidiol injection of 10mg/kg; N = 6M, 6F); 
and a cannabidiol high dose group (ketamine injection followed by a cannabidiol injection of 
20mg/kg; N = 6M, 6F). Behavioural testing occurred in a Y-maze and open-field, where both 
normal and stereotyped behaviours were recorded, as well as locomotor activity and spatial 
memory. Ketamine successfully induced stereotypy but failed to induce hyperlocomotion. 
Findings support the potential antipsychotic effects of CBD, particularly for reducing 
stereotypic behaviour in females. Results found data trends that suggest sex differences in 
responsiveness to CBD when administered with ketamine, although further research is 
needed due to lack of statistical significance.  
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1.0 Introduction 
1.1 General Overview 
The general aim of this research was to further investigate the antipsychotic properties 
of cannabidiol (CBD). This research also aimed to contribute to the increasing body of 
literature surrounding this topic. The following introduction discusses mental illness 
generally, before moving on to schizophrenia specifically, and its currently available 
treatments. The various hypotheses of the aetiology of schizophrenia will also be considered, 
with an emphasis on the glutamate hypothesis and NMDA receptor antagonists. Several 
animal models of schizophrenic-like symptoms will be outlined. Cannabinoids - with specific 
reference to cannabidiol - will be examined, and research into cannabidiol as an antipsychotic 
will be discussed before outlining the specific aims and hypotheses of the present study. 
 
Approximately 1 in 5 (20.7%) New Zealanders will have experienced mental illness 
at some point in the last 12 months, with 46.7% of the population meeting criteria for a 
disorder at some point in their lifetime (Oakley Browne, Wells, & Scotts, 2006). Due to 
national public awareness campaigns aiming to reduce stigma and discrimination (Ministry of 
Health, 2007) society is becoming more aware about mental illness. However, the individuals 
affected can still struggle with discrimination from much of society, and this can influence 
the impact that mental illness has on the individual in terms of every day functioning and 
their recovery. A study by Peterson and colleagues stated that individuals with mental illness 
reported discrimination most frequently by friends and family (59%) and when searching for 
employment (34%) (Peterson, Pere, Sheehan, & Surgenor, 2007). Effective treatments are 
immensely important for these individuals, as is support to maximise quality of life. 
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The costs of mental illness in this country and internationally, both short and long 
term are huge. To take one amongst a large number of examples: an overrepresented 
proportion of prison inmates in New Zealand suffer from a mental illness (with inmates 
having approximately twice the rate of most illnesses than the general population), and many 
of these go untreated. For example, 63% of inmates suffering from psychosis fail to receive 
treatment, as do 53.6% with major depression and 58.6% suffering from posttraumatic stress 
disorder (Brinded, Simpson, Laidlaw, Fairley, & Malcolm, 2001). This can lead to the 
situation where an incarcerated individual who suffers from mental illness will be released 
from prison back in to the community, and in the absence of proper treatment and support, 
that individual may rapidly be caught back up in the legal system, and be re-incarcerated. 
This so-called ‘revolving door’ phenomenon has significant costs for all parties involved, 
including local and wider communities. Not only is it vital for the individuals who suffer 
from illness to be able to have access to a treatment that works for them, but is also important 
for society as whole. 
 
Schizophrenia, with its combination of symptoms ranging from cognitive impairments 
and social withdrawal to hallucinations and delusions, is the most debilitating and costly 
mental illness (Combs & Muester, 2007). Affecting approximately 1% of the global 
population (Furuta & Kunugi, 2008; Julien, 2008), a range of effective treatments is required. 
As will be discussed, research in to the illness, its aetiology and treatments have come a long 
way, but with so many individuals who do not respond well to conventional medications and 
the side effects that often accompany them, researchers continue to strive to understand more 
about the illness and how to treat it.  
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1.2 Schizophrenia 
Schizophrenia is a mental illness that presents itself with a range of both positive and 
negative symptoms, as well as cognitive impairments such as deficits in memory, learning 
and attention. Schizophrenia was first recognised as a disorder in the early 1900s by 
Kraepelin, who named the illness ‘dementia praecox’ after observing a number of symptoms 
including paranoia and emotional blunting in patients (Andreasen, 1997). Although 
historically there has been some debate surrounding what symptoms should be included in 
schizophrenia diagnosis, it is undoubtedly characterised by deficits in social functioning, 
difficulties in looking after oneself, and intellectual impairments (Combs & Muester, 2007). 
These symptoms are currently necessary criteria in most current systems for diagnosis 
(Combs & Muester, 2007). 
 
Due to the effects of these symptoms, individuals diagnosed with schizophrenia often 
fail to remain independent and stay in their own homes. It has been reported that a substantial 
percent (25-60%) of patients rely on relatives as caregivers, and others often end up in mental 
health institutions and residential units. A study in the United States of America found that 
many individuals who fall through the system may end up in jail, with rates of the mentally ill 
in jails rising back up to that of the 1800’s, when it was common practice for those with 
mental illness to be incarcerated. Currently 7.2% of prison inmates suffer from serious mental 
illness, many of whom are being held without criminal charges having been laid against them 
(Torrey et al., 1992). 
 
Schizophrenia onset usually occurs around late adolescence and early adulthood. 
Childhood onset may occur, although this is less likely (Asarnow & Asarnow, 2003) and 
there is some debate as to whether or not this is the same disorder (Combs & Muester, 2007). 
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It has also been shown that women tend to develop schizophrenia later in life than men. It has 
been suggested that this may be attributed to menopause (Lees, Hallak, Deakin, & Dursun, 
2004) and therefore, women may be protected to some extent from developing schizophrenia 
due to the protective qualities of oestrogen. Females also present with more positive 
symptoms than men, and men with more negative symptoms than women (Lees, et al., 2004). 
 
The positive symptoms of schizophrenia “are noted by an excess or distortion of 
normal behaviour or cognition (e.g., hallucinations and delusions), and are usually a 
distressing experience for the client” (Rollins, Bond, Lysaker, McGrew, & Salyers, 2010, p. 
209). These symptoms are often episodic and the rapid onset contributes to the disturbance of 
everyday life. Three major positive symptoms that individuals present with are 
hallucinations, delusions and disorganised behaviour. Hallucinations occur in about 75% of 
individuals with schizophrenia (Combs & Muester, 2007) and can be auditory, visual, 
olfactory or tactile. The most common of these is auditory hallucinations, occurring in 74% 
of patients (Sartorius, Shapiro, & Jablensky, 1974). The prevalence of visual hallucinations is 
much lower (10-15%, Combs & Muester, 2007). Delusions may be bizarre (e.g. that the 
person can control thought), but are most commonly persecutory (e.g. imagining that people 
are trying to harm them) with persecutory delusions occurring in 64% of patients (Sartorius, 
et al., 1974). Other positive symptoms include stereotyped behaviour. In patients diagnosed 
with schizophrenia, stereotypy presents itself as repetitive and functionless motor behaviours 
(Morrens, Hulstijn, Lewi, De Hert, & Sabbe, 2006). Little is known about the course of 
stereotypy in schizophrenia, unlike cognitive symptoms which are relatively stable.  
 
The negative symptoms of schizophrenia are considered to be the lack or absence of 
normal human qualities, such as the loss of motivation, the blunting of emotions, poverty of 
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speech, lack of pleasure and social withdrawal (Julien, 2008; Rollins, et al., 2010). These 
symptoms are likely to be stable and continue for the course of the illness (Rollins, et al., 
2010). Similarly, cognitive symptoms can be ongoing. Symptoms include deficits in learning, 
working memory, attention and processing information, and difficulties in abstract reasoning 
(Combs & Muester, 2007). In the late 1960s, an international study in to schizophrenia 
conducted by Sartorius and colleagues reported that 97% of patients had a lack of insight 
(Sartorius, et al., 1974). These symptoms play a significant role in the degree to which 
everyday tasks become too difficult for the individual (Leifker, Bowie, & Harvey, 2009). 
 
Depending on the types of symptoms displayed, schizophrenia is referred to as 
paranoid, disorganised, catatonic, residual or undifferentiated (Barlow & Durand, 2005). 
Diagnosis in to these subtypes is dependent on which symptom criteria the individual meets.  
Comorbidity often occurs with negative mood, depression, and substance abuse in adults 
(Combs & Muester, 2007), and conduct disorders and depression in children (Asarnow & 
Asarnow, 2003). Due to low mood, suicide rates are high in adults (Combs & Muester, 2007). 
 
These symptoms all have a massive impact on the quality of life of the individual 
(Hoffmann, Kupper, & Kunz, 2000). A study of the relationship between symptoms and life 
outcomes for residential patients found that hallucinations, suspiciousness and social skills all 
predicted functioning outcomes. Furthermore, all predictive variables (including symptoms) 
only accounted for 40% of the variance, suggesting that symptoms aside, other environmental 
factors contribute to everyday functioning (Leifker, et al., 2009).  
 
Using data from the Mental Health Information National Collection (MHINC), Kake 
and colleagues estimated that there is a higher prevalence of schizophrenia for Maori than for 
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non-Maori. These estimates took into consideration socioeconomic deprivation and age. It 
has been reported that adolescent Maori males have a higher prevalence of cannabis use. 
Since the use of cannabis has been related to the development of schizophrenia, this may 
explain some of the increased prevalence in Maori (Kake, Arnold, & Ellis, 2008). Another 
study also found differences in treatments used for various ethnic groups in New Zealand, 
including Maori and Pacific people. It has been suggested that differences in metabolism may 
be important between ethnic groups and that some ethnic groups may be more sensitive to 
certain receptors, meaning they respond differently to various pharmacological treatments 
(Wheeler, Humberstone, & Robinson, 2008). This again demonstrates the importance for a 
variety of treatments, as not all individuals respond to the same medications. 
1.2.1 Treatment 
Some individuals who suffer from schizophrenia do not benefit from conventional 
medications and treatments. Further understanding of potential treatments for decreasing 
schizophrenic symptoms is valuable to those individuals and families affected by the illness, 
and to those involved in the mental health sector and the wider community. 
 
Before the discovery of antipsychotic agents, patients with schizophrenia were 
ostracised from society and many were permanently hospitalised, or as previously noted, 
prior to the 19
th
 century, even jailed (Torrey, et al., 1992). In the 1930’s electroconvulsive 
therapy was used, which often caused broken bones for the patient, and in the 1940’s, 
prefrontal leucotomies (the destroying of the frontal cortex with a blunt knife) was common 
(Rosenbloom, 2002). The development of medications that alleviate symptoms has allowed 
many individuals with schizophrenia to lead typical lives, when previously they almost 
certainly would not have this opportunity.  Although a number of medications are now 
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available, many of them have side effects which cause patients to stop taking them when their 
symptoms improve. This often leads to a relapse of symptoms and deterioration in 
functioning, and sometimes even rehospitalisation. Research into novel and effective 
medications with fewer side effects is ongoing and continuously needed.  
 
In the mid 1950s, phenothiazines were discovered, and although the drugs were first 
developed as antihistamines, the discovery of their sedative properties soon followed. After 
the use of phenothiazines such as promethazine and chlorpromazine by surgeons and 
anaesthesiologists, French research psychiatrists Delay and Deniker studied the effects of 
chlorpromazine on schizophrenic patients (Delay & Deniker, 1955). The researchers found 
the drug to be successful in alleviating mania and psychotic symptoms (Rosenbloom, 2002). 
Following this breakthrough, a number of other drugs with fewer side effects were developed 
over time, starting with analogues of the phenothiazines (Julien, 2008; Mailman & Murthy, 
2010). 
 
Currently, a variety of antipsychotics are available, which are categorised on the basis 
of when they were discovered. The first-generation or “typical” antipsychotics, such as those 
mentioned above, are effective in decreasing positive symptoms, but are often accompanied 
by a range of extrapyramidial side-effects (EPS) such as movement disorders. Typical 
antipsychotics can also exacerbate or even induce negative and cognitive symptoms in the 
patient (Keltner & Johnson, 2002). Both the clinical efficacy and the EPS of these 
antipsychotics, are a result of their dopamine D2 receptor antagonism (Julien, 2008; Keltner 
& Johnson, 2002). 
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In the late 1980s, a second generation of antipsychotics appeared. These second 
generation or “atypical” antipsychotics are typically preferred for treatment as they do not 
cause EPS, although other side-effects such as weight gain have been associated with them. 
Atypical antipsychotics are more effective than typical antipsychotics in treating negative 
symptoms. This has been attributed to their blocking of serotonin 5-HT2 receptors, as well as 
their D2 receptor antagonism (Julien, 2008; Keltner & Johnson, 2002). However, this 
explanation has also been disputed, reasons for which will be discussed below (Kapur & 
Remington, 2001).  
 
It is now thought that there may be a new third-generation of antipsychotics, although 
at present, most are still described as either “typical” or “atypical”. Aripiprazole, a recently 
available antipsychotic, and is thought to be in this category. What sets this drug apart from 
earlier antipsychotics is that it is a partial D2 receptor agonist, and this is thought to allow it 
to stabilise the dopamine system (Keltner & Johnson, 2002; Mailman & Murthy, 2010). It is 
also worth noting that atypical antipsychotics are now used for other various disorders such 
as bipolar disorder, personality disorders, and dementia (Julien, 2008). The implications of 
discovering novel drugs that may work for a variety of people and have minimal side effects 
are immeasurable.   
1.2.2 Aetiology of Schizophrenia 
 
Although the causes of schizophrenia are not entirely understood, various factors that 
include biological factors, stress, sex, ethnicity, structural brain abnormalities and 
psychosocial deficiencies have been linked to the illness. As previously noted, there are sex 
and ethnic differences in the prevalence of schizophrenia, and potentially in the effectiveness 
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of certain treatments. It has also been hypothesised that stress may contribute to the 
development of schizophrenia, particularly in individuals who may be vulnerable (e.g. have a 
genetic predisposition). There are a number of areas of the brain that are thought to be 
implicated in the aetiology of schizophrenia. Consistent findings from clinical and post-
mortem research show that the hippocampus has a significantly lower volume in patients that 
have been diagnosed with schizophrenia than controls (Keilhoff, Bernstein, Becker, 
Grecksch, & Wolf, 2004). It has also been widely shown that patients with schizophrenia 
have a significantly lower overall brain volume. These abnormalities are thought to occur 
during foetal development (Asarnow & Asarnow, 2003).  
 
It has been widely recognised that schizophrenia appears to be highly hereditary 
(Nieratschker, Nöthen, & Rietschel, 2010). This finding has sparked debate of whether this is 
due to biological factors or learned behaviour. Adoption and twin studies have been 
important in this respect, and have supported the role of genetics. Although having a parent 
with schizophrenia increases the risk of developing the illness, it is not inevitable (Combs & 
Muester, 2007). This is demonstrated by the fact that even in identical twins, who share 100% 
of the same genes, one may develop the illness and the other may not. The implication of this 
is to suggest an interaction between genetic vulnerability and environment. While these are 
all considered to be contributing factors to the aetiology of schizophrenia, a neurochemical 
component is still sought (Emrich, Leweke, & Schneider, 1997).  
 
A number of models have been developed around the changes observed in various 
neurotransmitter systems in patients diagnosed with schizophrenia. As can be seen above, the 
majority of antipsychotics have been considered in terms of their actions on the dopamine 
system, and this is where the focus of much research into novel antipsychotics has been 
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directed. However, as more research is conducted on the pharmacological basis of 
schizophrenia, more models and hypotheses of the illness’ development are emerging.  
1.2.2.1 Dopamine Hypothesis 
 
There is still wide acceptance of the dopamine hypothesis of schizophrenia, which 
was the dominant theory of the aetiology of the illness for decades (Haracz, 1982; Itokawa, 
Arinami, & Toru, 2010; Matthysse, 1974). This hypothesis posits that an excess release of 
dopamine or a possible heightened sensitivity to dopamine receptor neurons is the cause of 
the positive symptoms associated with schizophrenia (Mailman & Murthy, 2010). 
 
The involvement of dopamine was first suggested in the 1970’s after a number of 
early studies found that current neuroleptics were associated with changes in dopamine. 
Studies that tested the cerebrospinal fluid of schizophrenic patients attributed changes in 
brain dopamine to be due to the administration of chlorpromazine, clozapine and haloperidol 
(Gerlach, Koppelhus, Helweg, & Monrad, 1974). Another study involving cats found that the 
administration of L-Dopa (the precursor of dopamine) induced a range of stereotypic 
behaviours, which provided evidence that an excess of dopamine, or hypersensitivity to it, 
may have been related to schizophrenic disorders (Stevens, Wilson, & Foote, 1974). An early 
review by Matthysse concluded that the bulk of evidence available at the time supported the 
dopamine hypothesis, although there were a number of limitations and contradictions that 
were, at the time, yet to be resolved (Fyro, Wode-Helgodt, Borg, & Sedvall, 1974; Matthysse, 
1974). 
 
11 
 
Although many still strongly support this hypothesis, there are those who are moving 
towards other explanations for the dopamine abnormalities seen in patients with 
schizophrenia. Moncrieff concluded that contradictory results from post-mortem studies 
showed that schizophrenic symptoms being caused by over activity of dopamine are in fact 
not supported by current evidence. The author then suggested that dopamine antagonists may 
only reduce the intensity of symptoms, rather than target underlying mechanisms of the 
illness (Moncrieff, 2009). It has also been suggested that dopamine abnormalities are actually 
the result of abnormalities that lie in other neurotransmitter systems (see section 1.2.2.4). 
1.2.2.2 Serotonin Hypothesis 
The serotonin system is also believed to be involved in schizophrenia aetiology. 
During the development of atypical antipsychotics, improvements in patients were 
hypothesised to be due to 5-HT2 receptor antagonism (Julien, 2008). As noted previously, the 
notion that serotonin is responsible for the improvements seen by use of atypical versus 
typical antipsychotics have been disputed. This is mainly due to the fact that, as well as 
atypical antipsychotics, some typical antipsychotics have a high affinity for serotonin 
receptors, and that some substances that have a high affinity for serotonin receptors alone are 
not able to help with schizophrenia symptoms (Kapur & Remington, 2001). There is also 
evidence that supports an interaction between dopamine and serotonin. However, Meltzer 
emphasised that since atypical antipsychotics are able to control psychotic symptoms better 
than typical antipsychotics and alleviate extra-pyramidal side effects, serotonin antagonism is 
important in schizophrenia aetiology (Meltzer, 1992). Thus, although there seems to be a role 
for serotonin, this role is not entirely clear  
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1.2.2.3 Cannabinoid Hypothesis 
It has been suggested that the endogenous cannabinoid system may also be involved. 
It was observed very early on that the effects of the Cannabis sativa plant, when consumed, 
closely resembled the symptoms of schizophrenia. A substantial body of research has used 
Cannabis sativa or its main active constituent, Δ9-tetrahydrocannabinol (THC), to model 
psychosis in humans (Koethe, Hoyer, & Leweke, 2009). For example, D’Souza and 
colleagues gave healthy participants either 2.5 or 5mg/kg of THC, or ethanol vehicle alone. 
Participants were tested for positive and negative symptoms, alterations in perception, and 
learning and recall. The authors found that THC induced positive and negative symptoms, 
significantly impaired recall and working memory, but surprisingly did not alter learning 
(D'Souza et al., 2004). In a subsequent study, the above methods were replicated with stable 
schizophrenic patients. Amongst their findings, the authors reported that THC induced the 
same symptoms listed above, and to a higher extent than in the healthy participants (D'Souza 
et al., 2005). 
 
It is thought that irregularities in the functions of cannabinoid receptors, particularly 
the cannabinoid CB₁ receptor, may be involved in schizophrenia. Human studies have found 
dysfunction in the CB₁ receptor in schizophrenia patients, and these abnormalities are 
thought to be involved in cognitive and memory impairment (Parolaro, Realini, Vigano, 
Guidali, & Rubino, 2010). CB₁ receptor antagonists (such as cannabidiol) have also been 
shown to attenuate pharmacological psychosis in various animal models of schizophrenia 
(Kölfalvi & Fritzsche, 2008). The endocannabinoid system has also been linked to the 
dopaminergic (Muller-Vahl & Emrich, 2008) and glutamatergic systems (Emrich, et al., 
1997). However, the interactions between these systems are not yet understood.  
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Although the link between schizophrenia and the endocannabinoid system is 
relatively well established, a cannabinoid hypothesis of schizophrenia is still being developed 
and is yet to be used as an animal model in much research (Emrich, et al., 1997). This is 
partially due to the fact that the endocannabinoid system was only discovered in the 1990’s, 
and therefore, there are still gaps in knowledge about the mechanisms of action of 
cannabinoids (Koethe, et al., 2009). Cannabinoids and the substance cannabidiol will be 
discussed in more detail below. It is worth noting that other neurotransmitter models have 
also been suggested such as the cholinergic, GABAergic and peptidergic models (Emrich, et 
al., 1997). With the hunt for a single cause of schizophrenia now diminished, current research 
points toward a more complex pattern of causes.  
1.2.2.4 Glutamate Hypothesis  
A current model that is receiving a great deal of interest is the glutamate hypothesis. 
Glutamate is the major excitatory neurotransmitter in the brain. There are both ionotropic 
(NMDA, AMPA and kainite) and metabotropic (mGlu receptors) glutamate receptors 
(Hansen, Petersen, & Hansen, 2006). It has been suggested that blockade of the ionotropic 
receptor, N-methyl-D-aspartate (NMDA), is responsible for a succession of events that mimic 
the appearance of psychosis and schizophrenic-like symptoms in both humans and animals 
(Large, 2007).  
 
The involvement of glutamate in schizophrenia was  established in the 1980s after 
researchers found that there was diminished glutamate in the cerebrospinal fluid of patients 
with the illness (Kim, Kornhuber, Schmid-Burgk, & Holzmuller, 1980). This suggested that 
glutamatergic abnormalities may be involved in the aetiology of schizophrenia. Support for 
this hypothesis includes  research which has shown that several features of the illness cannot 
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be explained by previous hypotheses alone, such as the dopamine hypothesis (Stone, 2009). 
Since glutamatergic deficiency has been shown to interact with dopamine (Tiedtke, Bischoff, 
& Schmidt, 1990), the effects that antagonists of the NMDA glutamate receptor can have on 
this and other neurotransmitter systems may provide a useful model for explaining 
schizophrenic symptomology. It is thought that since NMDA receptors regulate dopamine 
neurons, hypofunction of NMDA receptors may be responsible for the abnormal dopamine 
activity observed in patients with schizophrenia (Stahl, 2007). It has been proposed that this 
hypofunction of NMDA receptors results from neurodevelopmental abnormalities that occur 
while the glutamate synapses are forming (Stahl, 2007).  
 
Antagonists of the NMDA glutamate receptor, such as ketamine and phencyclidine 
(PCP), effect both dopamine as well as glutamate receptors (Seeman, 2009) and can also 
disrupt the neurochemistry of multiple brain regions (Gao, Elmer, Adams-Huet, & 
Tamminga, 2009). This may help explain why, unlike dopaminergic or serotonergic drugs of 
abuse which only induce effects resembling the positive symptoms of schizophrenia, 
substances such as ketamine and PCP can induce a range of positive and negative 
schizophrenia-like symptoms, as well as cognitive deficits in both animals and humans 
(Julien, 2008; Stone, Morrison, & Pilowsky, 2007). This suggests that many symptoms of 
schizophrenia are likely to be induced by NMDA receptor antagonism (Stone, et al., 2007). 
These substances can also cause stable schizophrenic patients to relapse (Stone, et al., 2007), 
and the administration of known antipsychotics can attenuate such induced effects 
(Bubeníková-Valešová, Horáček, Vrajová, & Höschl, 2008; Marcotte, Pearson, & Srivastava, 
2001). Therefore, this model of schizophrenia which is based on the glutamate system is 
useful for testing the potential of novel antipsychotics.  
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1.3 NMDA Glutamate Receptor Antagonists 
Three of the most studied NDMA receptor antagonists are PCP, MK-801 and 
ketamine. Both ketamine and PCP are now widely used as animal models of schizophrenia, 
and there is a growing amount of research on MK-801. These models of schizophrenia are 
based on our current understandings of the glutamate hypothesis.  
 
By blocking NMDA receptors, PCP and ketamine (both dissociative anaesthetics) can 
result in behavioural abnormalities when administered in sub-anaesthetic doses (Becker et al., 
2003; Wilson et al., 2005). In humans, ketamine and PCP can worsen symptoms or reinstate 
psychosis in remitted schizophrenic patients. In healthy volunteers, these substances can 
induce psychotic episodes, cognitive disturbances, hallucinations and alter mood (Breese, 
Knapp, & Moy, 2002; Lahti, Weiler, Michaelidis, Parwani, & Tamminga, 2001; Stone, et al., 
2007). A study by Vollenweider and colleagues found that in healthy males, ketamine 
produced a dissociative state and schizophrenia-like symptoms (Vollenweider, Vontobel, 
Øye, Hell, & Leenders, 2000). Similarly, auditory sensory memory is impaired by ketamine 
(Umbricht et al., 2000). 
 
In animal models, PCP, ketamine and MK-801 induce hyperactivity and stereotypy. 
MK-801 is reported to induce stereotyped behaviours such as repetitive sniffing, and these 
effects are delayed and shortened by the antipsychotic haloperidol, and antagonised by 
clozapine (Tiedtke, et al., 1990). PCP has been reported to disrupt learning and memory in a 
variety of maze tests (Furuta & Kunugi, 2008) and induce cognitive deficits, which have then 
been attenuated by antipsychotics such as clozapine (Amitai, Semenova, & Markou, 2007). 
Although PCP is still readily used in animal studies, it is no longer used in controlled human 
studies because of its neurotoxicity. Ketamine however, induces similar effects but is less 
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toxic (Jentsch & Roth, 1999). Because of this, the present research focussed on ketamine as 
an animal model.  The effects of the substance are described in more detail below.  
1.4 Animal Models 
Although it is impossible to produce an animal model that is a complete reproduction 
of schizophrenia in humans, a number of current models show certain characteristics of the 
disorder  (Furuta & Kunugi, 2008). These models are crucial for understanding the aetiology 
and mechanisms of schizophrenia, and are important for developing treatments for the 
disorder. As previously noted, ketamine has been widely used as an animal model in 
schizophrenia research due to its NMDA receptor antagonism. The present study therefore 
focussed on ketamine and previous research involving current models of the behavioural 
assessment of schizophrenic-like symptoms. 
1.4.1 Locomotor Activity 
One of the most widely used measures of the drug-induced positive symptoms of 
schizophrenia is changes in locomotor activity. This is partly due to the fact that locomotor 
activity can be easily measured and quantified. Locomotor activity is typically measured by 
recording the number of squares a rodent crosses in an open field thereby providing an 
indication of the distance travelled. It is believed that this model assesses sensory information 
processes that may underlie some symptoms of schizophrenia (Geyer & Moghaddam, 2002). 
With regards to the glutamate model of schizophrenia, it has been widely reported that the 
administration of NMDA antagonists induces hyperactivity in rodents.  
 
Rodvelt and colleagues administered ketamine to rats daily for 30 days. Locomotor 
activity was assessed at the end of the 30 day period, in an open field. The authors reported 
17 
 
that rats that had received 30-50mg/kg ketamine displayed significantly higher levels of 
hyperactivity than rats administered saline (Rodvelt, Kracke, Schachtman, & Miller, 2008). 
Similarly, Hayse and colleagues reported hyperlocomotion in rats 15 minutes after receiving 
30mg/kg ketamine. However, rats that received a dose of 100mg/kg displayed hypolomotion 
15 minutes later, followed then by hyperlocomotion after 60 minutes (Hayase, Yamamoto, & 
Yamamoto, 2006). Other authors have also reported a significant increase in locomotor 
activity in both mice (100mg/kg, Chatterjee, Ganguly, Srivastava, & Palit, 2010) and rats 
(60mg/kg, Leite, Guimaraes, & Moreira, 2008) for ketamine, MK-801 (0.4mg/kg, Leite, et 
al., 2008) and  PCP (2mg/kg, Sams-Dodd, 1998), thus further supporting this behavioural 
measure as a model in the glutamate hypothesis. 
1.4.2 Cognitive Abnormalities 
It is not possible to examine negative symptoms of schizophrenia such as 
hallucinations and delusions in animals, and other symptoms such as emotional withdrawal 
and apathy are difficult to model accurately. It is however possible to examine and measure 
changes in cognitive abnormalities such as learning and memory. NMDA antagonists have 
been shown to induce learning and memory deficits. Traverso and colleagues found that 
ketamine doses of 75mg/kg and 120mg/kg disrupted conditioned taste aversion in male rats 
(another widely used test for learning (Traverso, Ruiz, Camino, & De la Casa, 2008).  
  
Learning and memory can be tested in a variety of ways, usually in a maze test such 
as the Morris water maze task, radial-arm maze, or T-maze (Furuta & Kunugi, 2008). A 
widely used measure for learning and memory in rats is the Y maze. This apparatus has been 
used by Hughes (2001, 2004) for developing a test of responsiveness to brightness change in 
rats and thus a simple test of short-term spatial memory. By means of these tests, cognitive 
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changes can be assessed in animals that have been treated with a substance such as ketamine, 
thereby providing some insight into mechanisms underlying the cognitive changes that occur 
in schizophrenia.  
1.4.3 Stereotyped Behaviours 
As discussed previously, stereotypy is a positive symptom that often presents in 
schizophrenia. It has also been noted that normal individuals administered PCP exhibit 
stereotyped-like behaviours such as rocking and head shaking which are similar to what 
patients with schizophrenia may experience (Breese, et al., 2002). These symptoms are also 
observed in animal models of the illness. In rodent models, behaviours include but are not 
limited to, sniffing, grooming, reverse locomotion, head weaving, gnawing and circling. 
Frequencies of stereotyped behaviours in rats are usually observed in open fields or the like.  
 
Randrup and Munkvad explain that the stereotyped behaviours induced by 
amphetamines, which increase dopamine activity, are selective. Some specific behaviours are 
increased in frequency, whereas others are decreased. The authors note that in lower doses, 
behaviours such as sniffing, locomotion and rearing occur, and there is a decrease in 
grooming. At higher doses, grooming continues to decrease and eventually disappears, and 
both locomotion and rearing also begin to decrease as doses increase (Randrup & Munkvad, 
1974). This corresponds to literature on NMDA antagonists which describes a similar pattern 
of stereotypy as discussed below. The antagonism of stereotypy has also been shown with 
both typical antipsychotics such as haloperidol and atypical antipsychotics such as clozapine, 
thus further supporting the glutamate hypothesis of schizophrenia (Tiedtke, et al., 1990).  
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It has been shown that ketamine induces stereotyped behaviours, such as circling, 
when administered either chronically (Leccese, Marquis, Mattia, & Moreton, 1986) or 
acutely (Wilson, et al., 2005). Other stereotyped behaviours frequently recorded are reverse 
locomotion and head weaving (Kos et al., 2006; Wilson, et al., 2005; Wilson et al., 2007). 
Therefore, in the present study, reverse locomotion (backing), head weaving and circling 
were recorded and then combined to produce one overall measure of stereotypy, as has 
typified previous research (Zuardi, Rodrigues, & Cunha, 1991).  
1.5 Cannabinoids 
Cannabinoids are a family of molecules that display pharmacological properties by 
acting on cannabinoid receptors. At this point in time, the two cannabinoid receptors that 
have been identified are CB₁ and CB₂. CB₁ receptors are normally found in the central and 
peripheral nervous systems, whereas CB₂ receptors are normally found in the immune system 
(Pertwee, 2005). An increasing body of research supports the involvement of the CB₁ 
receptor in the aetiology of schizophrenia, and there is new emerging evidence to suggest a 
role of the CB₂ receptor (Ishiguro et al., 2010). Cannabinoids can belong to one of three 
groups: endogenous endocannabinoids, synthetic, or phytocannabinoids. Phytocannabinoids 
are those extracted from the Cannabis sativa plant and include Δ9-tetrahydrocannabinol 
(THC) and cannabidiol (CBD). Cannabinoids have been found to possess therapeutic 
capability in a range of areas. However, due to the psychotropic effects of THC, research 
surrounding its therapeutic use is the subject of much contentious debate. In contrast, CBD 
lacks the psychotropic effects of THC, and is therefore rapidly becoming a focus of 
therapeutic cannabinoid research. 
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1.5.1 Cannabidiol  
Cannabidiol (CBD) is a non-psychoactive component that makes up to 40% of the 
Cannabis sativa plant (Iuvone, Esposito, De Filippis, Scuderi, & Steardo, 2009). The 
substance was first isolated in 1940 by Adams and colleagues, and in 1963, Mechoulam and 
Shvo ascertained its structure and chemistry (Izzo, Borrelli, Capasso, Di Marzo, & 
Mechoulam, 2009; Scuderi et al., 2009). Although the mechanisms of action of CBD are not 
entirely understood (Grotenhermen, 2005), it has been shown that it has a low affinity for 
both CB1 and CB2 receptors (Mechoulam, Peters, Murillo-Rodriguez, & Hanus, 2007; 
Scuderi, et al., 2009) as well as 5-HT1A receptors (Izzo, et al., 2009). 
 
Recent literature has described a range of therapeutic effects of CBD (Mechoulam, et 
al., 2007). The compound has been shown to reduce anxiety induced by THC, thereby 
indicating an anxiolytic effect (Koethe, et al., 2009). It has also been suggested as a drug for 
neurodegenerative disorders due to its antioxidant, anti-inflammatory and neuroprotective 
actions (Iuvone, et al., 2009). Since, CBD toxicity in humans is extremely low (Iuvone, et al., 
2009), its potential for therapeutic use is considerable.  
 
The Cannabis sativa plant has been linked to the development of schizophrenia in its 
users. However, this link may be confined to the chronic use of THC. In actual fact, CBD has 
been shown to attenuate the effects of THC (Emrich, et al., 1997), and to resemble the profile 
of current antipsychotic drugs, thus insinuating antipsychotic properties. A study by Morgan 
and Curran examined the levels of THC and CBD in cannabis users, and found that 
individuals who showed only levels of THC, presented with higher levels of positive 
schizophrenic-like symptoms than those with a combination of THC and CBD, supporting 
the opposing actions of the two constituents (Morgan & Curran, 2008). As CBD has potential 
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as a new and natural antipsychotic, further understanding of its effectiveness is valuable for 
those individuals suffering from schizophrenia who do not respond to more conventional 
methods of treatment.  
 
Zuardi and colleagues (Zuardi, Shirakawa, Finkelfarb, & Karniol, 1982) first 
discovered the antagonistic effect of CBD during a study of its interaction with THC. The 
authors found that the combination of the two drugs significantly attenuated the effects 
induced by the THC, and that this was not due to an interaction effect (Zuardi, et al., 1982). 
This was further investigated in a significant study (Zuardi, et al., 1991), in which several 
doses of CBD were compared with haloperidol (a typical antipsychotic) in male rats. CBD 
was shown to have similar effects to atypical antipsychotics, namely attenuating stereotyped 
behaviours (such as sniffing and biting) induced by apomorphine (a non-selective dopamine 
agonist). It was also shown that unlike haloperidol, CBD did not induce catalepsy (a 
movement disorder that involves the rigidity of muscles). A subsequent development was a 
study in which it was demonstrated that the antipsychotic effects of CBD were similar to 
those of haloperidol in a 19-year old patient suffering from schizophrenia (Zuardi, Morais, 
Guimaraes, & Mechoulam, 1995),. 
 
Moreira and Guimares (2005) further assessed the antipsychotic effects of CBD by 
testing its effectiveness in inhibiting the hyperlocomotion induced by both dopamine (using 
d-amphetamine) and glutamate (using ketamine) models of schizophrenia in male mice. 
These effects were compared to the typical antipsychotic haloperidol, and atypical 
antipsychotic clozapine. CBD was shown to inhibit the hyperlocomotion induced by D-
amphetamine, thus further supporting the dopamine model. Hyperlocomotion induced by 
ketamine was also inhibited by CBD, thereby providing additional support for the 
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glutamatergic model of schizophrenia, and adding support to the antipsychotic properties of 
CBD. Although clozapine and haloperidol also both inhibited the induced hyperlocomotion, 
they also decreased locomotion as compared to the control group. In contrast, CBD itself did 
not decrease locomotion (Moreira & Guimaraes, 2005). In accordance with earlier work by 
Zuardi et al. (1991), CBD and clozapine did not cause catalepsy, whereas haloperidol did, 
again suggesting that CBD may have a similar profile to the atypical antipsychotics.  
1.6 Sex Differences 
As previously noted, significant sex differences have been found between men and 
women who develop schizophrenia. Women have been shown to have a later onset than men, 
and tend to present with fewer negative and cognitive symptoms (Lees, et al., 2004).  Since 
males and females present with schizophrenia differently, it is important to include both sexes 
when conducting research into schizophrenia and its potential treatments. 
 
Ketamine, as discussed earlier, has been used to induce schizophrenic-like symptoms 
in both healthy volunteers, and in animal models. As with many areas of research, males 
(both animal and human) have been predominantly used. Prior to 2006, all previous human 
studies on ketamine at the time had either been conducted with male volunteers exclusively 
(for example see Vollenweider, et al., 2000), or with both males and females but in the 
absence of any distinctions being made between the two sexes (for example see Umbricht, et 
al., 2000).  Consequently, a call was made for more studies investigating possible sex 
differences in responsiveness amongst human volunteers (Lees, et al., 2004). The first study 
to investigate sex differences in ketamine’s effects on humans showed that male volunteers 
performed worse on a memory test than females, which is in line with sex differences in 
schizophrenia (Morgan, Perry, Cho, Krystal, & D'Souza, 2006). In animal models, although 
23 
 
the majority of research has also used males (Chatterjee, et al., 2010; Garcia et al., 2008; 
Hayase, et al., 2006; Leite, et al., 2008; Rodvelt, et al., 2008) there is now an increasing body 
of research that suggests females are more sensitive to ketamine than males. For example, in 
an early study Winters et al. (1986) found sex differences in analgesia, and that female rats 
lost their righting reflex for significantly longer than males, even though they were injected 
with a lower dose of ketamine (80mh/kg vs. 100mg/kg). A more recent study Wilson et al. 
(2005) found that ketamine induced reverse locomotion and headweaving in both sexes, but 
that these levels were significantly higher for females than for males. Ketamine also induced 
turning in females, but not in males, and decreased rearing regardless of sex (Wilson, et al., 
2005). These authors later reported similar results, with decreased locomotion and increased 
stereotypy in both sexes, and with ketamine becoming ineffective for older males but not for 
females (Wilson, et al., 2007). 
 
To date, no research investigating the antipsychotic effects of CBD has considered 
possible sex differences. Furthermore, few major studies using CBD in research in any field 
have examined sex differences. With regards to antipsychotic research, all rodent studies 
have used males (Moreira & Guimaraes, 2005; Zuardi, et al., 1991). Zuardi et al. (2006) used 
a small sample with both male and females human participants, but possible sex differences 
were not considered, as with an investigation of CBD’s effects on Parkinson’s disease 
(Zuardi et al., 2009). Most other CBD research has also involved males exclusively. Notable 
examples are studies the behavioural effects of CBD (Long et al., 2010) and its effects on 
stress (Bitencourt, Pamplona, & Takahashi, 2008; Resstel et al., 2009). This leaves a 
significant gap in current CBD research generally and specifically in antipsychotic research.  
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2.0 Aims and Hypotheses 
 
The present research was intended to further investigate the antipsychotic potential of 
CBD by investigating its effectiveness in a glutamate (ketamine) animal model of 
schizophrenia, taking into account possible sex differences in responsiveness to the 
compound. The main limitation of previous research, as already discussed, is the lack any 
consideration of potential sex differences in the antipsychotic effects of CBD. The current 
research involved both male and female rats and both a high and low dose of CBD. 
 
As mentioned previously, it is hypothesised that the glutamate system may be 
involved in the aetiology of schizophrenia, and that antagonists of the NMDA glutamate 
receptor are able to induce positive and negative symptoms as well as cognitive symptoms. 
Since ketamine has a range of effects that are likely to be induced by NMDA antagonism, the 
current research involved the use of ketamine as a model for schizophrenia. The reason for 
using ketamine rather than PCP is that, since PCP is no longer used in human studies, more 
information about ketamine could be useful for future research (Jentsch & Roth, 1999). The 
acute effects of CBD were accordingly tested after ketamine administration.  
 
Firstly, it was hypothesised that the administration of ketamine would induce 
schizophrenic-like behaviours in the rat. These behaviours include hyperlocomotor activity, 
stereotypic behaviours and learning and memory deficits, as measured in an open field and Y 
maze. Decreases in ‘normal’ behaviours such as grooming (Randrup & Munkvad, 1974) were 
also included. Secondly, based on findings from previous research, it was hypothesised that 
there would be significant sex differences in ketamine’s effects. Specifically, it was 
hypothesised that females would show higher levels of locomotor activity. It was also 
hypothesised that ketamine would induce more stereotyped behaviour in the females than in 
25 
 
the males. This seemed likely in view of previous research describing sex differences in the 
same stereotyped behaviours (circling, backing and head weaving, Wilson, et al., 2005). 
Because of expected sex-related differences, the data from male and female rats were 
statistically analysed separately for effects of CBD on the action of ketamine. 
 
It was hypothesised that CBD would alter the effects induced by the ketamine. It was 
proposed that CBD would modify any effects of ketamine so that the outcomes would be 
similar to those of the saline condition. In line with previous research, it was not expected 
that CBD on its own would decrease locomotion (Moreira & Guimaraes, 2005). Therefore, 
any changes observed between the ketamine-only and the ketamine/CBD conditions would 
be attributed to a combination of the two drugs. Specifically, it was hypothesised that CBD 
would decrease ketamine-induced hyperlocomotion (Moreira & Guimaraes, 2005) and, in 
line with previous observations (Zuardi et al., 1991), would attenuate ketamine-induced 
stereotyped behaviours. As there is no previous research on record of sex differences in 
responsiveness to CBD, it was not possible to predict how males and females would react.  
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3.0 Method 
3.1 Subjects 
The subjects were 24 male and 24 female PVG/C Hooded Rats, which were breed at 
the University of Canterbury, New Zealand. The rats were housed in groups of three of the 
same sex in large cages, with free access to communal food and water. The temperature-
controlled environment (temperature 22 (± 2)
O
 C and humidity 48 (± 10)%) was on a 12 hr 
light/dark cycle. All testing occurred during the light cycle.  
 
Cages were randomly assigned to one of four experimental groups. These were as 
follows: the saline only control group (saline injection followed by second saline injection); 
ketamine only group (ketamine injection followed by saline injection); cannabidiol low dose 
group (ketamine injection followed by a cannabidiol injection of 10mg/kg); and a cannabidiol 
high dose group (ketamine injection followed by a cannabidiol injection of 20mg/kg). All 
testing occurred between the ages of PND170 and PND245, during adulthood. All procedures 
were approved by the University of Canterbury Animal Ethics Committee (see Appendix A). 
3.2 Drugs and Rationale for Doses 
Ketamine was purchased from Provet NZ in a concentration of 100mg/ml and was 
diluted in sterile 0.9% saline to be administered via intraperitoneal injection (i.p.) in a dose of 
30mg/kg. This dose was based on previous research which has predominantly used doses 
between 30mg/kg and 50mg/kg in rats (Becker, et al., 2003; Hayase, et al., 2006; Keilhoff, et 
al., 2004; Rodvelt, et al., 2008). Using a dose at the lower end of this range was decided upon 
because of an indication from other unpublished research within the department suggesting 
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that PVG/C rats may be particularly sensitive to drugs, and it has been reported that ketamine 
effects may be affected by strain of rat (Large, 2007). 
 
Dr. Raphael Mechoulam (Hebrew University, Jerusalem, Israel) kindly supplied 
powdered cannabidiol (CBD). It was dissolved in Tween-80 and sterile 0.9% saline 
(Bitencourt, et al., 2008; Moreira & Guimaraes, 2005) and administered via intraperitoneal 
injection at a dose of either 10mg/kg or 20mg/kg. A fresh batch of the drug was made up 
daily before administration. These doses were based on previous research where CBD has 
been administered to rats in doses ranging from 1mg/kg- 60mg/kg (Moreira & Guimaraes, 
2005; Resstel, et al., 2009; Zuardi, et al., 1991). As noted earlier, it appears that the rats used 
within the department may be particularly sensitive to drugs, thus lower doses of CBD were 
selected for use. All solutions were injected at a volume of 1mL/kg. 
Table 1: Conditions and doses for male and female rats. First injection (horizontal) by second 
injection (vertical)  
  
 
 
 
 
 
3.3 Materials  
Rats underwent testing in both an open-field chamber and a Y-maze apparatus. These 
two pieces of equipment are explained in more detail below, followed by an explanation of 
procedure and assessment of behaviours that were recorded during these tests. 
 Ketamine 
30mg/kg 
Saline 1mL/kg 
Saline 0.9%  1mL/kg 6 M 6 F 6 M 6 F 
CBD 10mg/kg 6 M 6 F - 
CBD 20mg/kg 6 M 6 F - 
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3.3.1 Open field 
The open field apparatus comprised a 60 X 60 X 30cm box with transparent Perspex 
walls. The floor was black and divided into a white-lined grid of 16 numbered squares. A 
timer with an ear piece that produced an auditory signal every three seconds was also used to 
record the rats position and behaviour in the chamber. 
3.3.2 Y-Maze 
The wooden Y maze consisted of two 45cm long arms and a 15cm long stem, all 
10cm wide and 14cm high. A clear Perspex lid covered the top of the entire Y-maze. Black 
and white aluminium inserts could fit into the arms of the maze, to test for responsiveness to 
change and short-term spatial memory (see sections 1.4.2 and 3.4.1.2). The experimenter 
used a PC computer and keyboard with specialised software to record the movement of each 
rat within the maze. 
3.4 Procedure 
The subjects were randomly allocated to one of 4 groups in each of which were 6 
males and 6 females. One group received intraperitoneal saline (0.9%) alone followed 
immediately by another saline injection (as per the procedure for ketamine-treated rats 
described below). This served as a control for the rats that received ketamine and water, in 
order to provide a baseline for the changes that the ketamine alone induced. All other rats 
received ketamine (30mg/kg) via intraperitoneal injection, followed immediately by the 
relevant dose of saline or CBD (also via intraperitoneal injection).  
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3.4.1 Behavioural Assessment 
All testing occurred within the light phase of the light/dark cycle. Rats were injected 
and tested on both behavioural tests (open-field and Y-maze) during the same day, and this 
was the only behavioural testing each animal experienced. The rats were injected in a 
separate testing room from where they were housed. Twenty minutes post-injection, the rat 
was tested in the open-field, and then in the Y maze, before being returned to its cage. The 
testing apparatus was cleaned with a solution of 20% Powerquat blue and 80% water after 
each use.  
3.4.1.1 Open-Field Testing 
Twenty minutes post injection, the rat was placed into the centre of the open field and 
locomotor activity and stereotypic behaviour were recorded for five minutes. Every three 
seconds, the location of the rat was recorded, as were any behaviours that rat was engaged in. 
The location of the rat allowed the researcher to estimate the general locomotor activity by 
calculating the number of changes that were recorded for that animal during the five minutes. 
Instances of normal behaviours, rearing and grooming, were recorded every three seconds 
during the five-minute trial. Faecal boluses for each rat at the end of the test were also 
recorded. Higher levels of defecation and grooming are an indication of increased 
emotionality in the rat, whereas lower levels of exploratory behaviours (such as rearing) are 
an indication of anxiety (Belzung, 1999).  
 
Instances of abnormal “stereotypic” ketamine-induced behaviours were also recorded, 
namely circling, backing, and head weaving. Using definitions from previous research, 
circling was recorded when the rat rotated its body in a complete turn; backing was recorded 
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when the rat took two or more steps backwards; and head weaving was defined as “the rat 
slowly and rhythmically weaving its head from side to side” (Wilson, et al., 2007, p. 204). 
 
3.4.1.2 Y-maze Testing 
Immediately after completion of the open-field test, the rat was placed in the proximal 
end of the stem of a wooden Y maze. The Y-maze test measures responsiveness to change, 
anxiety, and short-term spatial memory (Hughes & Maginnity, 2007).  
 
The test began with a 6-min acquisition trial in which the rat was able to move freely 
between the two arms of the maze. One of the arms contained a black insert, and one a white. 
Half or the rats were randomly allocated to a group in which the white insert was in the right 
arm and, for the other half, it was in the left. At the end of the acquisition trial, the rat was 
removed while the arm inserts were replaced with two clean black inserts meaning that, one 
arm remained unchanged while the other (novel) changed arm had changed from white to 
black.  The rat was again placed in the stem of the maze, this time for a 3-min retention trial 
in which the first arm entered (novel or unchanged), time spent in each arm, and the number 
of entries to each arm were recorded by an observer making use of PC and keyboard. An 
estimate of locomotor activity was calculated by recording the total number of entered in to 
both arms. Typically, rats will enter the changed arm first, and will make more entries and 
spend more time in the novel/changed arm (Hughes, 2004). 
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4.0 Statistical Analysis 
 
This study intended to examine the effects of both low dose and high dose 
administration of CBD after ketamine administration. The hypothesis was that cannabidiol 
would alleviate ketamine-induced effects. The statistical program Statistica 9 was used for all 
analyses. Separate 4 (condition) x 2 (sex) factorial AVOVAs were performed on each 
measure, and post hoc Fishers PLSD tests were used for comparisons between specific 
groups when main effects were significant.  
 
Males and females were analysed separately, since it was expected that there would 
be significant differences between sexes due to ketamine administration- shown by previous 
research. 
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5.0 Results 
 
Throughout the results section the conditions will be referred to as follows:  
S/S= saline injection followed by second saline injection (control group); K/S= ketamine 
injection followed by saline injection; K/10= ketamine injection followed by cannabidiol low 
dose injection of 10mg/kg; and K/20= ketamine injection followed by cannabidiol higher 
dose injection of 20mg/kg. 
 
Since it was highly likely that the two sexes could differ significantly in the effects of 
ketamine (Wilson, et al., 2005; Wilson, et al., 2007), one-way ANOVAs were performed on 
each behavioural measure for males and females separately. Overall sex differences (for all 
drug groups combined) were determined by separate F tests.  
5.1 Open-field Results 
For the purposes of minimising the effects of high variance and thus facilitating the 
application of ANOVAs to the data, individual scores of 0 for defaecation and stereotypy 
were converted to 0.01. Also, the different examples of stereotyped behaviour (circling, head 
weaving and backing) were summed to produce a single stereotypy score, meaning F(3,68) in 
Table 1 and F(1,142) in Table 2. 
 
Effects of the drug treatments on each individual open-field measure for males and female 
separately are described in the following subsections.  Results of the ANOVAs for these 
treatments can be seen in Table 2. Overall sex differences for each open-field response are 
outlined in Table 3. 
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Table 2: Results of ANOVAs for effects of the drug treatments on males and females separately 
Male 
 
F  
 (3,20) 
P 
   
   
Rearing 87.265 <0.0001 
Grooming 3.2642 <0.05 
Defecation 3.3900 <0.05 
Locomotion 21.993 <0.001 
Centre Occupancy 2.9171 0.059 
Corner Occupancy 1.2562 0.319 
Stereotypy 3.50 <0.05 
   
Female 
Condition 
F  
 (3,20) 
P 
   
   
Rearing 155.3945 <0.0001 
Grooming 8.1929 <0.001 
Defecation* 4.0000 <0.05 
Locomotion 3.0305 0.053 
Centre Occupancy 4.2306 <0.05 
Corner Occupancy 8.0163 <0.01 
Stereotypy 5.42 <0.01 
 
 
 
Table 3: Mean (± SEM) frequencies of each open-field measure for male and female rats (all drug 
groups combined), and results of F tests for sex differences 
Sex  Male  
(n=24) 
Female  
(n=24) 
 F  
 (1,46) 
P 
       
       
Rearing  5.46 (1.92) 5.33 (1.74)  0.0023 0.962 
Grooming  1.08 (0.42) 2.46 (1.06)  1.4459 0.235 
Defecation*  0.71 (0.26) 0.17 (0.10)  3.8296 0.056 
Locomotion  36.04 (3.03) 42.29 (3.57)  1.7803 0.189 
Centre Occupancy  33.88 (5.07) 39.75 (5.87)  0.5734 0.453 
Corner Occupancy  26.63 (3.77) 20.92 (3.71)  1.1626 0.287 
Stereotypy*□   3.63 (0.97) 16.75 (3.13)  16.06 <0.001 
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5.1.1 Rearing 
Effects of the drug conditions on rearing for males and females separately are outlined in 
Figure 1.  
 
Figure 1: Mean (± SEM) frequencies of rearing for male and female rats separately following each 
type of drug treatment. 
 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
There was a significant effect of condition on rearing with all drug groups showing 
significantly less rearing than the controls for both male and female rats. There were no 
significant overall sex differences. 
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5.1.2 Grooming 
Effects of the drug conditions on grooming for males and females separately are outlined in 
Figure 2.   
 
Figure 2: Mean (± SEM) frequencies of grooming for male and female rats separately  following 
each type of drug treatment. 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
Grooming was significantly decreased in all drug conditions compared to controls for both 
male and female, and there was no significant overall sex difference.   
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5.1.3 Defecation 
Effects of the drug conditions on defecation for males and females separately are outlined in 
Figure 3.   
 
Figure 3: Mean (± SEM) frequencies of defaecation for male and female rats separately  following 
each type of drug treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
There was a significant effect of condition with rats in each drug condition producing fewer 
faecal boluses than S/S rats for both male and female. There was no significant overall sex 
difference. 
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5.1.4 Locomotor Activity 
Effects of the drug conditions on locomotor activity for males and females separately are 
outlined in Figure 4.  
 
Figure 4: Mean (± SEM) frequencies of locomotor activity for male and female rats separately 
following each type of drug treatment. 
 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
For males, there was a significant effect of condition with rats in each drug condition having 
less locomotor activity than controls. For females, there was a significant effect of condition 
on locomotor activity with ambulation decreasing across each drug condition from S/S. There 
was no significant overall sex difference. 
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5.1.5 Centre Occupancy 
Effects of the drug conditions on centre occupancy for males and females separately are 
outlined in Figure 5.   
 
Figure 5: Mean (± SEM) frequencies of centre occupancy for male and female rats separately 
following each type of drug treatment. 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
There was significantly more centre occupancy for all drug conditions for both male and 
female than for S/S, but there was no significant overall sex difference. 
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5.1.6 Corner Occupancy 
Effects of the drug conditions on corner occupancy for males and females separately are 
outlined in Figure 6.   
 
Figure 6: Mean (± SEM) frequencies of corner occupancy for male and female rats separately 
following each type of drug treatment. 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
There was significantly less corner occupancy for all drug conditions than for S/S for both 
male and female, but there was no significant overall sex difference. 
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5.1.7 Stereotypy  
Effects of the drug conditions on stereotypy for males and females separately are outlined in 
Figure 7.   
 
Figure 7: Mean (± SEM) frequencies of stereotypy for male and female rats separately following 
each type of drug treatment. 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
Stereotypy was significantly higher in all drug conditions than controls for both sexes, and a 
significant sex difference revealed that females display more stereotypy than males. 
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5.2 Y-Maze Results 
Effects of the drug treatments on each individual Y-maze measure for males and female 
separately are described in the following subsections.  Results of the ANOVAs for these 
treatments can be seen in Table 4. Overall sex differences for each Y-maze measure are 
outlined in Table 5. 
 
Table 4: Results of ANOVAs for effects of the drug treatments on males and females separately. 
Male 
Condition 
 
F  
 (3,20) 
P 
   
Total Time in Both Arms 2.0895 0.134 
% Time in Novel  3.66 <0.05 
Total Entries Both Arms 7.0206 <0.01 
 % Entries Novel 1.8397 0.173 
   
Female 
Condition 
 
F  
 (3,20) 
P 
   
Total Time in Both Arms 1.8652 0.168 
% Time in Novel  0.61 0.619 
Total Entries Both Arms 0.2522 0.859 
% Entries Novel 0.4439 0.724 
   
 
 
Table 5: Mean (± SEM) frequencies of each Y-maze measure for male and female rats (all drug 
groups combined), and results of F tests for sex differences 
Sex 
 
 
 
 
Male 
(n=24) 
Female 
(n=24) 
 
 
F  
 (1,46) 
P 
       
Total Time in Both Arms  43.91 (10.08) 71.76 (9.98)  3.8542 .056 
% Time in Novel   6.93 (1.68) 19.29 (4.23)  8.5100 .006 
Total Entries Both Arms  1.88 (0.40) 3.50 (0.34)  9.5504 <.01 
% Entries Novel  43.08 (7.35) 55.35 (5.30)  1.8336 .182 
       
 
* F(1,6) because the means of each group were compared against each other, not individual subject 
scores. 
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5.2.1 Total Time Spent in Both Arms 
Effects of the drug conditions on the total amount of time spent in both arms for males and 
females separately are outlined in Figure 8.    
 
Figure 8: Mean (± SEM) total amount of time spent in both arms for male and female rats 
separately following each type of drug treatment. 
 
  
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
The difference between the two groups with superscripts in common is significant (Fisher PLSD test, 
P<0.05) 
 
There was no significant difference of condition for either sex, nor any significant 
interactions. 
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5.2.2 Percentage of Time Spent in the Novel Arm 
Effects of the drug conditions on the percentage of time spent in the novel arm for males and 
females separately are outlined in Figure 9.   
 
Figure 9: Mean (± SEM) percentage of time spent in the novel arm for male and female rats 
separately following each type of drug treatment. 
 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
The difference between the two groups with superscripts in common is significant (Fisher PLSD test, 
P<0.05) 
 
For males, there was a significant effect of condition with rats in each drug condition 
spending less percentage of time in the novel arm than controls. There was no significant 
condition effect for females, nor a significant overall sex difference. 
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5.2.3 Total Number of Entries in Both Arms (Locomotor Activity)  
Effects of the drug conditions on the total number of entries in to both arms for males and 
females separately are outlined in Figure 10.   
Figure 10: Mean (± SEM) frequencies of the total number of entries in to both arms for male and 
female rats separately following each type of drug treatment. 
 
 
*significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
 
General mobility scores were calculated for each condition by taking the sum of entries in to 
each arm. For males, there was a significant effect of condition with rats in each drug 
condition having lower levels of locomotor activity than controls. For females, there was no 
significant difference of condition, however there was a significant overall sex difference, 
with females having higher levels of locomotor activity than males.  
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5.2.4 Percentage of Entries in to Novel Arm  
Effects of the drug conditions on the percentage of entries in to the novel arm for males and 
females separately are outlined in Figure 11.   
Figure 11: Mean (± SEM) percentage of entries in to the novel arm for male and female rats 
separately following each type of drug treatment. 
 
 
 *significantly different from control (S/S) group (P<0.05, Fishers PLSD test). 
The difference between the two groups with superscripts in common is significant (Fisher PLSD test, 
P<0.05) 
 
There was no significant difference of condition for either sex, nor any significant overall sex 
difference. 
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6.0 Discussion 
6.1 General Summary 
The present research aimed to further investigate the antipsychotic effects of CBD in 
a glutamate (ketamine) model of schizophrenia. Due to the lack of previous research 
investigating sex differences with respect to responsiveness to the compound, one of the 
primary aims of this research was to examine the possible differences. As such, both male 
and female rats were used. A lower and a higher dose of CBD were also examined. In this 
section, the findings of the study will be discussed in comparison with previous research on 
CBD. Strengths and limitations of the present study will also be discussed, along with 
implications and suggestions of further research.  
 
Overall, the results showed that in some instances, CBD had the ability to attenuate 
ketamine-induced behaviours in the rat. However, due to limitations that will be discussed in 
this section, these results should be viewed with caution. Perhaps the most important finding 
was the presence of sex differences observed in the conditions involving CBD. This research 
highlights the lack of literature investigating sex differences in CBD responsiveness, and 
calls for future research to focus on this. 
6.2 Ketamine-induced Effects 
Based on the glutamate hypothesis of schizophrenia etiology, effects of the NMDA 
receptor antagonist ketamine were used as an animal model of schizophrenia. It was 
hypothesised that the administration of ketamine would induce a range of psychotic-like 
symptoms in the rat. These symptoms included an increase in locomotor activity, deficits in 
learning and memory, and induced stereotyped behaviours, as measured in an open field and 
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a Y maze. In previous research, doses ranging from 30mg/kg-100mg/kg have been used 
(Becker, et al., 2003; Hayase, et al., 2006; Rodvelt, et al., 2008).  However, the lower dose of 
30mg/kg was selected for the present research because of an as yet untested likelihood that 
PVG/C Hooded rats may display a heightened sensitivity to various substances, compared 
with some more commonly used strains. 
 
It was hypothesised that ketamine would induce hyperlocomotion. This was based on 
a vast body of research in which hyperlocomotion has been used as a measure in animal 
models of schizophrenia (Hayase, et al., 2006; Leite, et al., 2008; Rodvelt, et al., 2008; Sams-
Dodd, 1998). Contrary to the hypothesis, the administration of ketamine did not induce 
hyperlocomotion in either sex, and instead it decreased locomotor activity in both sexes. 
Ketamine decreased locomotion in males more than females, although there was no overall 
sex difference (see Figure 4). It is therefore possible that this lack of locomotion contributed 
to the lack of stereotypy observed in the male rats, as will be discussed below. These changes 
in locomotor activity were also observed in the Y-maze testing, with the total number of 
entries in to both arms being significantly reduced for males but not for females. 
 
As noted, a substantial body of literature supports hyperlocomotion as a ketamine 
model of schizophrenic-like behaviour. The most likely explanation for why this research 
failed to come to the same conclusions as previous research is that the dose of ketamine was 
too high. As previously noted, it has been found that PVG/C Hooded rats appear to be 
particularly sensitive to some substances. Although this was taken into consideration, with a 
lower dose of 30mg/kg being used, this dose may have still been too high, particularly for 
males. This is supported by literature that suggests that higher doses of ketamine will induce 
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hypolocomotion, followed by hyperlocomotion (Becker, et al., 2003). If the dose was indeed 
too high, a longer test period may have shown an increase in locomotor activity over time.  
 
As was expected, none of the stereotyped behaviours that were measured (circling, 
backing and head weaving) were present in the control groups of either sex. As hypothesised, 
these abnormal behaviours were successfully induced by ketamine administration in both 
males and females. It was also hypothesised that there would be a higher rate of stereotypy in 
the females than in the males. The current research supported this hypothesis, demonstrating 
that the females displayed significantly more stereotyped behaviours than males (see Figure 
7).  
 
At first glance this suggests that females may have been more sensitive to the effects 
of ketamine. This explanation is supported by previous research that has shown similar sex 
differences, and attributed this to possible mechanisms such as differences in hormones or 
metabolism, and the female oestrous cycle (Wilson, et al., 2005).  However, it is important to 
note that when looking at these data in combination with the data on locomotor activity, it 
appears that males may have needed a lower dose of ketamine, suggesting that they may have 
been more sensitive to the substance. As has been discussed, ketamine produced a significant 
drop in locomotor activity for males, more so than for females. Due to a lack of voluntary 
movement in the males, they may not have had the opportunity to display stereotyped 
behaviours. Given that the females retained more movement following ketamine 
administration, they were probably able to display high levels of stereotyped behaviours. It is 
proposed that a more accurate impression of stereotypy in males would have been provided if 
the ketamine dose had been lower, thus retaining higher levels of locomotor activity. This 
would have also allowed for a more precise evaluation of sex differences in this measure. 
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It was also hypothesised that ketamine would induce a decrease in ‘normal’ 
behaviours. Previous research has found that grooming is significantly decreased with 
ketamine administration (Randrup & Munkvad, 1974). The current research produced results 
that were consistent with this, namely a significant decrease in grooming for both males and 
females but with no overall significant sex difference in this measure. Similarly, rearing was 
also decreased for both sexes, with no overall sex differences. Lower levels of rearing, like 
with other measures of exploratory behaviour, are an indication of heightened anxiety. 
However Wilson and colleagues (2005) noted that this decrease may be attributed to ataxia 
produced by ketamine, thereby causing deficits in coordination and balance which would 
hinder the rats’ ability to rear.  
 
It was hypothesised that ketamine would induce deficits in learning and memory, as 
measured in the Y maze. This apparatus has been used to test responsiveness to change in rats 
which is dependent on short-term spatial memory (Hughes, 2001, 2004). Typically, rats will 
make more entries in to the novel/changed arm and spend more time in this arm (Hughes, 
2004). For the K/S conditions, the percentage of time spent in the novel arm was decreased 
for both sexes, but neither of these was significant. Likewise, the percentage of entries in to 
the novel arm was decreased for both sexes, but these were not significant. It may be that 
ketamine had some effects on responsiveness to change and spatial memory, but a lack of 
statistically significant results did not support this possibility.  
 
Frequency of defaecation during testing in the open-field was also recorded. An 
increase in defaecation was used as a measure of heightened anxiety. There were normal 
levels of defaecation present in the S/S conditions of both sexes, and there were no instances 
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of defaecation in the K/S conditions for either sex. This significant reduction in defaecation is 
consistent with previous research which has attributed this outcome to the anxiolytic effect of 
the substance (Zuardi & Guimares, 1997). Centre and corner occupancy were also recorded. 
For both sexes, ketamine increased time spent in the centre of the apparatus, as shown by an 
increase in centre occupancy and a decrease in corner occupancy. This increase in centre 
occupancy was significant for males but not females, and the decrease in corner occupancy 
was significant for females but not for males. This is usually an indication of decreased 
anxiety, which is consistent with the results showing decreased defaecation, and the 
anxiolytic effect of ketamine. However, since the subjects were placed in the centre of the 
apparatus during testing, this may simply be a reflection of the decrease in ambulation. 
6.3 Cannabidiol (CBD) effects 
The main focus of this research was the antipsychotic potential of CBD in a ketamine 
model of schizophrenia, taking into account possible sex differences. To date, no studies have 
considered sex differences in responsiveness to the drug. Immediately after ketamine 
administration, CBD was administered in either a low (10mg/kg) or high (20mg/kg) dose, in 
both males and females. As with ketamine, although doses much higher than this have been 
used in previous research (Zuardi, et al., 1991), lower doses were adopted due to the 
possibility that PVG/C Hooded rats may be more sensitive to various drug effects. Based on 
previous research (Moreira & Guimaraes, 2005; Zuardi, et al., 1991), it was hypothesised that 
CBD would attenuate the ketamine-induced effects described above. It is important to note 
that CBD was always administered with ketamine, so possible effects of the compound can 
only be considered in terms of this combination.   
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It was hypothesised that CBD would decrease ketamine-induced hyperlocomotion, as 
has been previously reported (Moreira & Guimaraes, 2005). Although ketamine did not 
increase locomotor activity as expected, there was evidence that CBD decreased locomotion 
when administered post-ketamine. It has been shown that CBD on its own will not decrease 
locomotor activity (Moreira & Guimaraes, 2005), so although CBD was always administered 
in combination with ketamine, the observed changes in this study are worthy of noting. For 
females, both doses of CBD with ketamine decreased locomotor activity further, suggesting 
an additive effect of both drugs. As can be seen in Figure 4, ketamine alone did not 
significantly reduce locomotor activity for females, but the decrease resulting from ketamine 
and the high dose of ketamine was significant. If the ketamine had induced hyperlocomotion, 
it would be reasonable to hypothesise that CBD would have had the potential for bringing 
locomotor activity back down to a similar level to that of the controls. However, a further 
study demonstrating this is needed. For males, the CBD conditions made no difference in 
locomotor activity compared to the ketamine-alone condition. This highlights a sex difference 
in the effects that CBD may have on activity levels in the rat when co-administered with 
ketamine.  
 
As noted, ketamine successfully induced stereotypy in the rat. It was hypothesised 
that the subsequent administration of CBD would attenuate these effects, as has been shown 
for other animal models of schizophrenia (Zuardi, et al., 1991). For females, the subsequent 
administration of the low CBD dose with ketamine decreased instances of stereotypy as 
compared with the ketamine only condition, however this was not significant. The high dose 
of CBD decreased these behaviours further, suggesting that a higher dose again may have 
continued this downward nonsignificant trend and may have eliminated the behaviours 
altogether. For males, although ketamine induced stereotypy, this was lower than for females. 
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It is suggested that the dose of ketamine may have been too high for males, as supported by 
the levels of locomotor activity exhibited by the subjects (as discussed above). For males, the 
low (but not the high) dose of CBD decreased ketamine-induced stereotypy, although the 
difference between this low dose with ketamine and ketamine on its own was not significant. 
Without further research, it cannot be concluded that these effects were due to the 
combination of CBD and ketamine, or ketamine alone. The differences in CBD effects on 
stereotypy were quite different for males and females, highlighting the importance of testing 
with both sexes.  
 
With regard to ‘normal’ behaviours, CBD administration along with ketamine made 
little difference to grooming. For males, both doses of CBD appeared to decrease grooming 
further, suggesting an additive effect. For females, the low dose reinstated low levels of 
grooming, however the high dose did not. Again, it is important to point out sex differences 
in the effects of CBD administration. Similarly, ketamine almost completely diminished 
rearing in both males and females, and CBD administration made little difference to this 
measure.  
 
It was hypothesised that ketamine could induce learning and memory deficits, and 
that CBD would attenuate these effects. Although ketamine did decrease the time spent in the 
novel arm and the percentage of entries for both males and females, these changes were not 
significant. Interestingly, the effects that CBD in combination with ketamine had on males 
and females were vastly different. As can be seen in Figure 9, for males, the low dose of 
CBD decreased the percentage of time spent in the novel arm, and the high dose significantly 
decreased this further. These results for females were the reverse with the low dose of CBD 
increasing the percentage of time spent in the novel arm and the high dose increasing this 
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again. However, none of these conditions were significant. Although this leaves contradicting 
results on the actions of CBD in this measure, it does highlight the sex differences of CBD 
under the same conditions. As would be expected, the results were remarkably similar with 
regards to the percentage of entries in to the novel arm. As can be seen in Figure 11, for 
males, the low dose of CBD with ketamine decreased the percentage of entries in to the novel 
arm, and this was significantly decreased further by the high dose. For females, CBD 
increased this measure with the low dose, and increased it further with the high dose, 
although none of these conditions were significant. Since no research has fully investigated 
sex differences in CBD, the possible reasons behind these differences are not known. 
 
As can be seen in Figure 3, ketamine completely diminished defaecation frequency 
for both males and females. For males, CBD in combination with ketamine increased 
defaecation in both dose conditions. This did not occur for females, again highlighting sex 
differences. For males, centre occupancy was significantly increased by ketamine, and this 
was decreased by CBD administration in both dose conditions, returning to a level that was 
not significantly different from the S/S condition. Likewise, ketamine had decreased corner 
occupancy, and this was increased by both CBD conditions. For females however, both doses 
of CBD continued to increase centre occupancy and decrease corner occupancy, suggesting 
an additive effect. Males and females responded very differently to CBD in this measure, 
however the mechanisms causing this difference are unknown.  
 
It is clear that there were significant sex differences in responsiveness to a 
combination of ketamine and CBD. This research suggests that the mechanisms of action of 
the combination may be different for males and females, although further research is needed 
to investigate this.  
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6.4 Strengths 
This study supported the use of ketamine for inducing schizophrenic-like stereotypy 
in both male and female rats. Sex differences were observed, which is in line with emerging 
literature that suggests females are more susceptible to ketamine-induced stereotypy than 
males (Wilson, et al., 2005). Although ketamine did not increase locomotor activity, 
hypolocomotion occurred in both the open field and Y maze, thus showing consistent 
recording of data. Additionally, this study effectively showed the potential antipsychotic 
actions of CBD in showing changes in behaviour when CBD and ketamine are administered 
together, particularly for females. However, additional research is needed to attribute these 
shown changes to CBD action.  
 
Although it was unknown if any sex differences would be present in the response to 
CBD, there is an increasing body of literature that suggests that sex differences are present in 
a range of other antipsychotic medications, and that males and females respond differently to 
treatment efficacy and side-effects (Smith, 2010). Although the mechanisms are not entirely 
known, it is thought that these discrepancies may be due to differences in hormones, 
metabolism, and physiology (Smith, 2010). By suggesting significant sex differences in the 
response to CBD in combination with ketamine, this research has not only supported these 
findings, but has also added new information to the field of CBD research.  
6.5 Limitations 
There were a number of limitations that may have compromised some of the findings 
reported in this study. Firstly, the dose for ketamine is thought to have been too high, 
particularly for the male rats. It is possible that this caused the lack of hyperlocomotion that 
was expected in both sexes, and also reduced stereotypy in males, therefore compromising 
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the ketamine model. It is suggested that this sensitivity to such a conservative dose of 
ketamine was due to the strain of rat. The validity of this research would have been improved 
if the current research had used a strain of rat that had been used previously in ketamine 
models, such as the Sprague-Dawley. However, this was not feasible in the university lab. A 
lack of previous research using a variety of strains of rat, means that, in the current study, 
some degree of speculation was required in selecting what doses would be appropriate for 
use.  If the ketamine dose was in fact too high, this then provides difficulty in interpreting the 
results of the subsequent CBD administration. In hind sight, an initial dose-response study of 
ketamine in both males and females would have been valuable in determining an appropriate 
dose to gain the desired effects.  
 
In addition, the current research investigated the acute effects of CBD post-ketamine 
administration. Improved methodology may have included measuring chronic effects of 
ketamine which may have mimicked the illness more closely. Previous research has used 
CBD as a pre-treatment to ketamine administration (Moreira & Guimaraes, 2005) or has 
administered a combination of two drugs at the same time (Zuardi, et al., 1991). It is 
unknown if any differences in results may be due to different methodologies, but it would be 
reasonable to assume that there may be differences in the mechanisms behind the drug 
effects, due to the order and/or combination of the drugs. It would have also been beneficial 
to have added a condition in which rats received CBD alone. This would have shown initial 
responsiveness to CBD and would have provided a baseline for comparison with the CBD 
plus ketamine conditions.  
 
This study was conducted on a small sample size. This means that the generalisability 
of these results is somewhat limited, and that more significant findings may have been 
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revealed with a larger sample. It is always possible with the nature of such research that an 
experimenter bias is present while recording data. It is unlikely that this occurred, and this is 
demonstrated by the lack of findings which would support the hypothesis of an increase in 
locomotor activity in the ketamine conditions. However, it would have been ideal if the 
experimenter was blind to the conditions, to rule out the potential of any such bias. This was 
not able to be done due to the unavailability of additional personnel.  
6.6 Implications 
To date, no research has considered the possible sex differences of CBD in a ketamine 
model of schizophrenia. The current research has suggested that there appears to be sex 
differences in the actions of CBD in combination with ketamine. However, with the 
exception of the Y-maze data, these differences lack statistical significance so that more 
research is obviously needed. These findings have significant implications for future research 
using CBD both generally and specifically in antipsychotic research. 
 
Cannabis based medications are starting to be prescribed to patients in some countries 
such as Canada. Some would argue that the current lack of knowledge in sex differences of 
these compounds means that prescribing such substances is premature. Sativex® is one 
example. This nasal spray is consists of a 1:1 ratio of THC and CBD (Nurmikko et al., 2007). 
It is primarily prescribed for pain and spasticity in multiple sclerosis, and appears to be 
beneficial for many patients. However, as with CBD research, research to date supporting the 
use of Sativex® appears to be lacking sex comparison studies. Most research has used only 
male participants, and those that have used both males and females have not considered sex 
differences. For example, a study investigating the effects of Sativex® in reducing spasticity 
in multiple sclerosis used both male and female participants but did not consider sex 
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differences (Collin, Davies, Mutiboko, & Ratcliffe, 2007). Similarly, a study on pain reported 
that both male and female participants could be recruited for the study, but failed to report the 
makeup of the actual participant pool (Nurmikko, et al., 2007). This raises the question “are 
possible sex differences being overlooked?” It may be that any sex differences that are 
present in the efficacy of this medication are minimal, but there is no way of ruling out 
significant differences without sufficient research. It also raises some concern over potential 
differences in side effects. Given that most studies have used only male participants, it is 
possible that there may be different side effects for females that have been overlooked. 
Again, this is all unknown due to a lack of relevant studies. The current research, although 
using only CBD and not the combination present in Sativex®, has drawn attention to a lack 
of research investigating sex differences in therapeutic cannabinoid research, and has 
indicated significant sex differences. With current research supporting CBD for a range of 
therapeutic uses, sex differences must be looked at more closely as we move forward in 
prescribing such drugs.  
6.7 Future Research Directions 
This study highlights several important areas for future research. Firstly, there is a 
major need for research that fully investigates the sex differences of CBD administration. A 
comprehensive sex and dose study is needed on CBD alone as it has been shown that 
potential sex differences are present. It is also proposed that future research using CBD in 
both antipsychotic studies and other fields should consider sex differences. The present study 
focused on three specific stereotyped behaviours, thus it is unknown what sex differences 
may present in other behaviours and measures of schizophrenic-like symptoms in the rat such 
as pre-pulse inhibition and social withdrawal. The possibilities of further research in this area 
are immense.  
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It has been clearly demonstrated that various strains of rat may show different degrees 
of sensitivity to certain substances (Varty & Higgins, 1994). Some differences between 
PVG/C Hooded and other strains have been demonstrated (Farook et al., 2001), although 
little research has specifically looked into drug sensitivity. However, there is an indication 
from other unpublished research within this laboratory suggesting that PVG/C rats may be 
particularly sensitive to drugs, as compared to some commonly used strains such as Sprague-
Dawley and Wistars. Firstly, it would be helpful to understand the differences between these 
strains of rats with regards to various commonly used drugs in the animal lab. A study that 
examines this would be valuable in assisting future research. Such a project is necessary so 
that future results can be compared with other research more accurately. An alternative 
proposal is that future research uses a strain that is more commonly used worldwide. This 
would ensure more accurate results, and allow for these to be generalised more easily. 
 
As noted, previous studies using CBD in schizophrenia research have used a range of 
methodologies. A study looking at possible differences of pre and post treatment would be 
beneficial. Overall, more research on CBD is needed. It is clear that the substance has 
antipsychotic potential, along with other therapeutic qualities, and due to its safety for human 
consumption, these avenues are worthy of further examination. With further research, a wide-
scale human trial will eventually be necessary. 
6.8 Conclusions 
Schizophrenia is the most debilitating and costly mental illness (Combs & Muester, 
2007) and affects approximately 1% of the population worldwide (Furuta & Kunugi, 2008; 
Julien, 2008). Many patients with this life-altering and chronic illness either do not respond 
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well to current treatments, or experience side effects which make medication compliance an 
issue. Research working towards potential alternative treatments is invaluable.  
 
Despite its limitations, the current research has supported the potential antipsychotic 
effect of CBD, as shown by trends in the discussed data, particularly for reducing stereotypic 
behaviour in female rats. However, since CBD was always administered in combination with 
ketamine, a lack of statistically significant differences between the CBD conditions and 
ketamine alone means that more research with a larger sample size is needed, along with a 
CBD alone condition to be able to attribute the observed effects to CBD action. This research 
has also highlighted that responsiveness to CBD in combination with ketamine differs 
between males and females under the same conditions. More research is needed, particularly 
with regard to possible sex differences. Future directions have also been proposed for 
investigating the impact different rodent strains may have on research outcomes. 
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